MedTrace Logo

Sleep, Awake & Move - Part II

NCT02710487 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2018-08-27

No results posted yet for this study

Summary

Sleep benefit (SB) is a prominent spontaneous, apparently unpredictable, transitory improvement in motor function reported by around 50% of patients affected by Parkinson's Disease (PD) after sleep and before taking their first dose of dopaminergic medications. The aim of this study is to test the hypothesis that objective and/or subjective improvement of motor function might be due to a carry-over effect of Rapid Eye Movements (REM) sleep at awakening from this sleep phase.

Conditions

  • Idiopathic Parkinson's Disease

Interventions

BEHAVIORAL

REMSA

Awakening from REM sleep during the last hour of the sleep period

BEHAVIORAL

NREMSA

Awakening from N2 (NREM) sleep during the last hour of the sleep period

Sponsors & Collaborators

  • Parkinson Schweiz

    collaborator OTHER

  • Ente Ospedaliero Cantonale, Bellinzona

    collaborator OTHER

  • Penn State University

    collaborator OTHER

  • Neurocenter of Southern Switzerland

    lead OTHER

Principal Investigators

  • Pietro Luca Ratti, MD, PhD · Neurocenter of Southern Switzerland

Study Design

Allocation
NON_RANDOMIZED
Purpose
OTHER
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-03
Primary Completion
2018-01-12
Completion
2018-07-27

Countries

  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02710487 on ClinicalTrials.gov